Protalix Biotherapeutics (NYSEAMERICAN:PLX) Shares Gap Up to $0.32

Shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) gapped up prior to trading on Tuesday . The stock had previously closed at $0.28, but opened at $0.32. Protalix Biotherapeutics shares last traded at $0.30, with a volume of 9,625 shares changing hands.

Several equities analysts have recently issued reports on PLX shares. Zacks Investment Research upgraded Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th. HC Wainwright set a $3.00 target price on shares of Protalix Biotherapeutics and gave the stock a “buy” rating in a research note on Friday, October 18th.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.02. The firm had revenue of $14.25 million for the quarter, compared to analysts’ expectations of $11.60 million. During the same period last year, the firm posted ($0.10) earnings per share.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A hedge fund recently raised its stake in Protalix Biotherapeutics stock. Renaissance Technologies LLC boosted its stake in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) by 7.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,326,528 shares of the company’s stock after acquiring an additional 308,823 shares during the quarter. Renaissance Technologies LLC owned about 2.92% of Protalix Biotherapeutics worth $2,029,000 as of its most recent filing with the Securities and Exchange Commission.

Protalix Biotherapeutics Company Profile (NYSEAMERICAN:PLX)

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.

Featured Story: What is the Book Value of a Share?

Leave a Reply

Your email address will not be published. Required fields are marked *

*